Evidence map›Paper›PMID 26565986›Full record

ArticlePloS one2015

Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis.

Philip P Becker, Monika Rau, Johannes Schmitt, Carolin Malsch, Christian Hammer, Heike Bantel, Beat Müllhaupt, Andreas Geier

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 5 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 5 syntheses or guidelines pooled it, 148 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Philip P BeckerDepartment of Gastroenterology and Hepatology, University Hospital Zürich (USZ), Zürich, Switzerland.
Monika RauDivision of Hepatology, University Hospital Würzburg (UKW), Würzburg, Germany.
Johannes SchmittDivision of Hepatology, University Hospital Würzburg (UKW), Würzburg, Germany.
Carolin MalschInstitute of Clinical Epidemiology und Biometry University of Würzburg, Würzburg, Germany.
Christian HammerSchool of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Heike BantelDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Beat MüllhauptDepartment of Gastroenterology and Hepatology, University Hospital Zürich (USZ), Zürich, Switzerland.
Andreas GeierDepartment of Gastroenterology and Hepatology, University Hospital Zürich (USZ), Zürich, Switzerland.
Universitätsklinikum Würzburg · DEÉcole Polytechnique Fédérale de Lausanne · CHMedizinische Hochschule Hannover · DEUniversity Hospital of Zurich · CHUniversity of Würzburg · DEUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesLiver biopsies are the current gold standard in non-alcoholic steatohepatitis (NASH) diagnosis. Their invasive nature, however, still carries an increased risk for patients' health. The development of non-invasive diagnostic tools to differentiate between bland steatosis (NAFL) and NASH remains crucial. The aim of this study is the evaluation of investigated circulating microRNAs in combination with new targets in order to optimize the discrimination of NASH patients by non-invasive serum biomarkers.

methodsSerum profiles of four microRNAs were evaluated in two cohorts consisting of 137 NAFLD patients and 61 healthy controls. In a binary logistic regression model microRNAs of relevance were detected. Correlation of microRNA appearance with known biomarkers like ALT and CK18-Asp396 was evaluated. A simplified scoring model was developed, combining the levels of microRNA in circulation and CK18-Asp396 fragments. Receiver operating characteristics were used to evaluate the potential of discriminating NASH.

resultsThe new finding of our study is the different profile of circulating miR-21 in NASH patients (p<0.0001). Also, it validates recently published results of miR-122 and miR-192 to be differentially regulated in NAFL and NASH. Combined microRNA expression profiles with CK18-Asp396 fragment level scoring model had a higher potential of NASH prediction compared to other risk biomarkers (AUROC = 0.83, 95% CI = 0.754-0.908; p<0.001). Evaluation of score model for NAFL (Score = 0) and NASH (Score = 4) had shown high rates of sensitivity (91%) and specificity (83%).

conclusionsOur study defines candidates for a combined model of miRNAs and CK18-Asp396 levels relevant as a promising expansion for diagnosis and in turn treatment of NASH.

Indexed as

AdultApoptosisBiomarkersBiopsyCase-Control StudiesCohort StudiesFemaleGene Expression ProfilingHumansLiverMaleMicroRNAsNon-alcoholic Fatty Liver DiseaseObesityRegression AnalysisROC CurveBiomarkersMicroRNAsMIRN122 microRNA, humanMIRN192 microRNA, humanMIRN21 microRNA, human

Identifiers

PMID26565986
PMCPMC4643880
OpenAlexW2174904675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.